Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7734044 | 0.86 | TSHR (0.65) | TSHRCYP3A4CYP1A2LMNACYP2C9 | |
| SCHEMBL11109738 | 0.85 | ALDH1A1 (0.68) | TSHRCYP3A4CYP1A2LMNACYP2C9 | |
| SCHEMBL751617 | 0.84 | LMNA (0.54) | TSHRCYP3A4CYP1A2LMNAALDH1A1 | |
| SCHEMBL13663882 | 0.84 | TSHR (0.57) | TSHRCYP3A4LMNAALDH1A1HSD17B10 | |
| SCHEMBL14577737 | 0.84 | TSHR (0.60) | TSHRCYP3A4CYP1A2LMNACYP2C9 | |
| SCHEMBL17912412 | 0.84 | TSHR (0.58) | TSHRCYP3A4CYP1A2LMNACYP2C19 | |
| SCHEMBL10246464 | 0.84 | CYP1A2 (0.70) | TSHRCYP3A4CYP1A2LMNACYP2C9 | |
| SCHEMBL12393858 | 0.84 | TSHR (0.65) | TSHRCYP3A4CYP1A2LMNACYP2C9 | |
| SCHEMBL30622008 | 0.82 | ATM (0.56) | TSHRCYP3A4CYP1A2LMNACYP2C19 | |
| SCHEMBL9850701 | 0.82 | TSHR (0.55) | TSHRCYP3A4CYP1A2LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| EP-1421069-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083304-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2213664-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| CN-1367780-A | Oxazolidinones and their preparing method and use thereof | UPJOHN CO (US) | 2002-09-04 | — | — | CN | disclosed |
| WO-1999001442-A1 | TRIAZINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | TSHR 3968/4885CYP3A4 16/4885CYP1A2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.